Krause Kevin Michael
Insider CIK 1916925 · ANTX Chief Strategy Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics, Inc. | A Award deriv | 2024-03-15 | 2024-03-18 | 60,000 | — | $0 | 60,000 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award | 2024-03-15 | 2024-03-18 | 30,000 | — | $0 | 31,914 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award | 2024-03-15 | 2024-03-29 | 30,000 | — | $0 | 31,914 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | M Exercise deriv | 2024-01-09 | 2024-01-11 | 5,000 | — | $0 | 26,832 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | M Exercise deriv | 2024-01-09 | 2024-01-11 | 2,417 | — | $0 | 49,868 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | M Exercise | 2024-01-09 | 2024-01-11 | 5,000 | $6.60 | $33.0K | 9,331 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2024-01-09 | 2024-01-11 | 7,417 | $20.14 | $149.4K | 1,914 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | M Exercise | 2024-01-09 | 2024-01-11 | 2,417 | $0.42 | $1.0K | 4,331 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | M Exercise deriv | 2024-01-02 | 2024-01-04 | 2,583 | — | $0 | 52,285 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2024-01-02 | 2024-01-04 | 2,583 | $20.12 | $52.0K | 1,914 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | M Exercise | 2024-01-02 | 2024-01-04 | 2,583 | $0.42 | $1.1K | 4,497 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award deriv | 2023-02-15 | 2023-02-17 | 62,200 | — | $0 | 62,200 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award deriv | 2022-05-12 | 2022-05-16 | 66,000 | — | $0 | 66,000 | SEC↗ |